Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination ta

June 22, 2026 -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervou

June 12, 2026 -- Transcend Therapeutics today announced the completion of its acquisition by Otsuka America Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. (Otsuka), marking a significant milestone in Transcend's mission to develop rapid-acting treatments for neuropsychiatric diseases, including post-traumatic stress disorder (PTSD). The acquisition was originally announced on March 27, 2026. With the completion of the transaction, Transcend is now a wholly owned subsidiary of Otsuka Amer

June 12, 2026 -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). According to the agreement, Simcere Pharmaceutical will fund the exploratory research of this first-in-class novel molecule. Upon successful completion, Simcere wil

Galmed Pharmaceuticals acquired Colospan in a $4.5 million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion. The deal calls for Colospan shareholders and SAFE (Simple Agreement for Future Equity) holders to get $2.5 million in cash and $2 million in common ordinary shares at the close, which is expected to be completed by the end of the second quarter this year, the company said in a June 8 press release. The sale has been

Incyte announced Monday an agreement to acquire Vega Therapeutics, a wholly-owned subsidiary of Star Therapeutics, for up to $2 billion, confirming rumours first reported by the Financial Times a day earlier. The deal — which includes $1.25 billion upfront — is focused on the investigational monoclonal antibody VGA039 for von Willebrand disease (VWD). "VGA039 fits directly into our strategy of building a top-tier growth company for the future," said Incyte CEO Bill Meury, who took up the reins

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan's device during H2 2026 in Europe with an initial focus on Germany, Austria and Switzerl

June 2, 2026 -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a liquid biopsy company focused on innovative diagnostics for cancer, and Neovia Oncology LLC, a Delaware based pharmaceutical company dedicated to developing novel oncology therapies, announced the signing of a strategic partnership agreement to collaborate on Neovia's upcoming studies treating patients with advanced multiple drug resistant solid tumors who are entering late lines of therapy. The collaboration is expe

June 2, 2026 -- SMi Systems announces today the execution of a non-exclusive evaluation collaboration with Luminex Corporation to assess the feasibility of using Luminex beads with SMi's single-molecule imaging platform and to compare SMi's analytical sensitivity with Luminex's current xMAP readers under defined test conditions. The evaluation is initially focused on research activities to validate the potential for SMi's technology to complement Luminex's industry leading xMAP technology. SMi

Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, gaining control of the latter's late-stage candidate sevasemten. The move comes on the heels of the French drugmaker's roughly $2.5-billion takeout of Day One Biopharmaceuticals earlier this year. Monday's transaction includes $1.55 billion in upfront cash and as much as $1.1 billion in regulatory and commercial milestones. Expected to close in the third quarter, the deal transfers to Servi